Gross Margin: ~89% - 92%
Sales Growth (Q/Q): ~40% - 60%
P/E (Current),~6.1 - 6.3,"Extremely low. The market is still cautious, which offers potential for a ""value"" investment."
Forward P/E,~10.8,"Slightly up from current, reflecting expected R&D investments in 2026."
Free Cash Flow,~$77M (for 2025),"The company has generated significant cash, ending 2025 with $154.6M in cash."
ROE,>200%,"The number is skewed upwards due to the recent move to profitability, but shows tremendous efficiency."
Debt/Equity,~0.3 - 0.5,"Low debt, which is excellent for the sector."
Revenue Growth,~25% - 60%,2026 forecast is for revenue between $275M and $290M.
PEG Ratio,n/a,Most platforms do not calculate this due to recent earnings volatility.
Dividend Yield,0%,Typical for biotech; reinvest everything in new developments (e.g. R289).
Analyst Rating,Strong Buy,Average analyst target is around $51.20 (potential for +35%).
Sales Growth (Q/Q): ~40% - 60%
P/E (Current),~6.1 - 6.3,"Extremely low. The market is still cautious, which offers potential for a ""value"" investment."
Forward P/E,~10.8,"Slightly up from current, reflecting expected R&D investments in 2026."
Free Cash Flow,~$77M (for 2025),"The company has generated significant cash, ending 2025 with $154.6M in cash."
ROE,>200%,"The number is skewed upwards due to the recent move to profitability, but shows tremendous efficiency."
Debt/Equity,~0.3 - 0.5,"Low debt, which is excellent for the sector."
Revenue Growth,~25% - 60%,2026 forecast is for revenue between $275M and $290M.
PEG Ratio,n/a,Most platforms do not calculate this due to recent earnings volatility.
Dividend Yield,0%,Typical for biotech; reinvest everything in new developments (e.g. R289).
Analyst Rating,Strong Buy,Average analyst target is around $51.20 (potential for +35%).
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.